Results 41 to 50 of about 6,465 (327)

Actinium-225 targeted alpha particle therapy for prostate cancer

Theranostics
Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment of prostate cancer (PCa). Actinium-225 (225Ac), a potent alpha-emitting radionuclide, may be incorporated into targeting vectors, causing robust and in some cases
A. Bidkar, Luann Zerefa, Surekha Yadav, H. VanBrocklin, R. Flavell   +4 more
semanticscholar   +1 more source

A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals

EJNMMI Radiopharmacy and Chemistry, 2021
Background As 225Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures.
James M. Kelly, Alejandro Amor-Coarasa, Elizabeth Sweeney, Justin J. Wilson, Patrick W. Causey, John W. Babich   +5 more
doaj   +1 more source

Biodistribution of free Francium-221 and Bismuth-213 in Tumour-bearing SCID mice after successful development of Actinium-225/Francium-221 radionuclide generator Set-up

European Journal of Nuclear Medicine and Molecular Imaging
Despite the clinical evidence of actinium-225 (225Ac)-based targeted alpha therapies (TαT) efficacy, optimized treatment regimens are needed to improve overall clinical response rates and decrease toxicities.
S. Zitzmann-Kolbe, Y. Remde, I. Moen, B. Madas, László Mázik, Frans Suurs, Steffen Happel, Martin Schäfer, Christoph Schatz, Harun Taş, U. Hagemann, M. Benešová-Schäfer   +11 more
semanticscholar   +1 more source

The parent of actinium [PDF]

Proceedings of the Royal Society of London. Series A, Containing Papers of a Mathematical and Physical Character, 1918
Abstract It has been recognised for more than a decade that actinium cannot be a primary radio-element, but hitherto all attempts to obtain evidence of its continuous production, in the same way as has been established for polonium and for radium, have met with no success. As our knowledge of radioactive change has become precise, the
Frederick Soddy, John A. Cranston
openaire   +1 more source

Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects

Cancers
Simple Summary This review assesses the potential of Actinium-225 and Bismuth-213 as leading radionuclides for targeted alpha therapy, highlighting their ability to deliver potent cytotoxic radiation with high tumor specificity.
Mohamed F. Nawar, A. A. Selim, B. Essa, Alaa F. El-Daoushy, M. M. Swidan, Claudia G. Chambers, M. A. Al Qahtani, Charles J. Smith, Tamer M. Sakr   +8 more
semanticscholar   +1 more source

Real-time trajectory imaging of alpha particles emitted from actinium-225 and its daughter radionuclides

Scientific Reports
In targeted alpha-particle therapy, actinium-225 (Ac-225) has emerged as a radionuclide of potential, driving extensive efforts to develop innovative radiopharmaceuticals.
S. Yamamoto, Masao Yoshino, K. Shirasaki, K. Nakanishi, Kei Kamada, Akira Yoshikawa, J. Kataoka   +6 more
semanticscholar   +1 more source

Is Actinium Really Happening?

Journal of Nuclear Medicine, 2023
T he most recent survey ( 1 ) related to a -radiotherapy development showed that 27 molecules labeled with 225 Ac are presently under development, among which 13 have already reached human test level.
R. Zimmermann
semanticscholar   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

OncoImmunology, 2021
Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority of patients. Targeted radionuclide therapy (
Kim De Veirman, Janik Puttemans, Ahmet Krasniqi, Thomas Ertveldt, Heleen Hanssens, Ema Romao, Dirk Hose, Cleo Goyvaert, Philip Vlummens, Serge Muyldermans, Karine Breckpot, Frank Bruchertseifer, Alfred Morgenstern, Matthias D’Huyvetter, Nick Devoogdt   +14 more
doaj   +1 more source

Numerical Solution of Radioactive Core Decay Activity Rate of Actinium Series Using Matrix Algebra Method [PDF]

, 2021
The Actinium 235 series is one of the radioactive series which is widely used as a raw material for reactors and nuclear activities. The existence of this series is found in several countries such as West USA, Canada, Australia, South Africa, Russia, and
Prihandono, Trapsilo, Prastowo, Sri Handono Budi, Pratiwi, Anita Puji   +2 more
core